Recida Therapeutics is a Menlo Park, CA-based biopharmaceutical company developing novel therapeutics for serious antibiotic-resistant infections. Its lead program, RC-01, is an IND-stage LpxC inhibitor targeting multidrug-resistant gram-negative infections. Recida licensed development and commercialization rights to RC-01 from FUJIFILM Toyama Chemical Co. Ltd. for all territories outside Japan and has a development partnership with MicuRx Pharmaceuticals for greater China. The company planned to submit an Investigational New Drug (IND) application for RC-01 to the U.S. FDA in Q1 2019 and anticipated completing a Phase 1 trial in 2019. Recida raised $8.5M in a Series A financing and also received an up to $4.4M award from CARB-X to fund IND preparation, the Phase 1 trial, and drug product manufacturing to support subsequent Phase 2 studies. Co-founders include CEO James Ge, MD, PhD, Vernon Jiang, PhD, George H. Talbot, MD, and Paul Eckburg, MD.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2019